IRIS
MINARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 783
NA - Nord America 756
AS - Asia 209
OC - Oceania 2
AF - Africa 1
Totale 1.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 753
IT - Italia 273
IE - Irlanda 208
SE - Svezia 160
CN - Cina 137
AT - Austria 31
DE - Germania 25
FI - Finlandia 25
HK - Hong Kong 16
TR - Turchia 16
SG - Singapore 14
IN - India 13
GB - Regno Unito 11
RU - Federazione Russa 8
BE - Belgio 6
NL - Olanda 6
FR - Francia 5
LU - Lussemburgo 5
RO - Romania 4
CA - Canada 3
JP - Giappone 3
MK - Macedonia 3
AU - Australia 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
ID - Indonesia 2
IL - Israele 2
MD - Moldavia 2
PK - Pakistan 2
UA - Ucraina 2
VN - Vietnam 2
ES - Italia 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
LT - Lituania 1
MY - Malesia 1
PL - Polonia 1
ZA - Sudafrica 1
Totale 1.751
Salva come PNG Salva come JPEG
Città #
Dublin 203
Chandler 200
Ann Arbor 84
Ashburn 75
Parma 73
Shanghai 48
Boardman 33
New York 31
Vienna 31
Beijing 26
Princeton 22
Bologna 18
Dearborn 16
West Jordan 16
Bremen 14
Milan 14
Verona 14
Izmir 11
Des Moines 10
Hong Kong 10
Wilmington 10
Los Angeles 9
Helsinki 8
Pune 8
Fremont 7
Jinan 7
Auburn 6
Brussels 6
Pavia 6
Redmond 6
Woodbridge 6
Bolzano 5
Changsha 5
London 5
Modena 5
Nanchang 5
Nanjing 5
Seattle 5
Shenyang 5
Bottanuco 4
Busseto 4
Cascina 4
Central 4
Ferrara 4
Hefei 4
Jacksonville 4
Trento 4
Wayne 4
Amsterdam 3
Houston 3
Istanbul 3
Kunming 3
Lonato 3
Norwalk 3
Redwood City 3
Rome 3
Rubiera 3
San Giuliano Milanese 3
Alcamo 2
Ayr 2
Bagnolo in Piano 2
Boston 2
Candiac 2
Carpenedolo 2
Chisinau 2
Desio 2
Dong Ket 2
Fairfield 2
Florence 2
Frankfurt am Main 2
Guangzhou 2
Hayamiya 2
Hebei 2
Karak 2
Leawood 2
Marino 2
Menteng 2
Minerbio 2
Neviano degli Arduini 2
Ningbo 2
Prata Di Pordenone 2
Reggio Emilia 2
Rio Saliceto 2
Rosate 2
Rottofreno 2
San Mateo 2
Skopje 2
Sofia 2
Tianjin 2
Torrile 2
Viggiù 2
Zevio 2
Adelaide 1
Alessandria 1
Amersfoort 1
Andover 1
Ankara 1
Arcole 1
Atlanta 1
Borås 1
Totale 1.210
Salva come PNG Salva come JPEG
Nome #
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 115
Evidence fo Epigenetic Abnormalities of the Androgen Receptor Gene in Foreskin from Children with Hypospadias 112
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 97
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 77
A novel mutation in the nr0b1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children. 71
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 69
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 68
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC 66
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 64
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 63
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 59
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 57
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 56
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 54
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 54
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition 53
Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: A case report 52
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 49
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 48
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 45
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 45
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 44
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 41
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 40
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 38
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 32
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: Review on emerged mechanisms of resistance 29
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 27
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 24
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 23
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 22
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 21
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 19
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 18
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 12
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 11
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 11
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 10
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 8
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 5
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 5
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 5
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 5
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 4
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 4
Totale 1.832
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201914 0 0 0 0 0 0 0 0 0 0 13 1
2019/2020139 15 15 6 3 6 15 20 7 12 21 14 5
2020/2021102 3 5 2 5 3 5 12 10 20 8 14 15
2021/2022215 19 8 10 16 11 2 43 10 17 3 20 56
2022/2023849 67 84 37 73 83 87 15 64 242 7 61 29
2023/2024455 30 24 15 28 58 89 62 35 36 70 8 0
Totale 1.832